necrot
enterocol
nec
among
common
devast
diseas
neonat
despit
signific
advanc
neonat
clinic
basic
scienc
investig
etiolog
larg
understood
specif
treatment
strategi
lack
morbid
mortal
remain
high
improv
understand
pathogenesi
nec
may
therapeut
consequ
pharmacolog
inhibit
tolllik
receptor
signal
use
novel
nutrit
strategi
microflora
modul
may
repres
novel
promis
approach
prevent
treatment
nec
review
start
recent
acquisit
pathogen
mechan
nec
focus
current
possibl
therapeut
perspect
rotaviru
candida
albican
pseudomona
aeruginosa
e
n
v
r
u
candida
glabrata
klebsiella
noroviru
aspergillu
fumigatu
cronobact
sakazakii
r
v
r
u
shigella
boydii
echoviru
coagulaseneg
staphylococcu
cytomegaloviru
clostridium
spp
c
x
c
k
e
v
r
u
campylobact
toroviru
enterobact
cloaca
coronaviru
salmonella
necrot
enterocol
nec
inflammatori
diseas
intestin
often
associ
sepsi
frequent
complic
perfor
periton
death
despit
signific
advanc
neonat
clinic
basic
scienc
investig
nec
often
incur
diseas
specif
therapeut
strategi
lack
unknown
etiolog
mortal
rate
high
longterm
prognosi
surviv
poor
inflammatori
process
start
intestin
mucosa
involv
distant
organ
includ
central
nervou
system
increas
risk
neurodevelop
delay
total
annual
estim
cost
care
affect
infant
nec
unit
state
rang
million
billion
reason
nec
becom
prioriti
research
term
necrot
enterocol
nec
often
reflect
spectrum
intestin
condit
differ
respect
pathogenesi
classic
form
nec
usual
occur
preterm
neonat
first
week
life
spontan
intestin
perfor
often
diagnos
nec
occur
term
neonat
could
observ
also
sever
day
birth
condit
probabl
repres
differ
diseas
differ
pathogenesi
independ
modal
feed
character
minim
intestin
inflamm
andor
necrosi
review
focus
recent
advanc
pathogenesi
potenti
therapeut
option
classic
form
nec
despit
fact
pathogenesi
nec
consid
multifactori
recent
role
epithelium
emerg
central
develop
nec
loss
epitheli
barrier
allow
pathogen
transloc
intestin
lumen
mucosa
figur
innat
immun
regul
epitheli
barrier
experiment
model
human
case
nec
intestin
mucosa
prematur
infant
present
persist
equilibrium
state
injuri
repair
injuri
intestin
mucosa
may
depend
varieti
condit
typic
prematur
includ
hypoxia
infect
starvat
microcirculatori
dysfunct
contribut
epitheli
damag
physiolog
condit
heal
epithelium
begin
immedi
injuri
matur
enterocyt
migrat
health
wound
area
subsequ
prolifer
new
enterocyt
within
crypt
lieberkuhn
complet
process
repair
recent
suggest
nec
associ
mark
inhibit
enterocyt
migrat
prolifer
make
host
uniqu
suscept
injuri
final
bacteri
transloc
role
tolllik
receptor
innat
immun
structur
compon
locat
epitheli
surfac
play
major
role
tissu
repair
tolllik
receptor
tlr
among
known
human
tlr
type
seem
crucial
role
nec
develop
may
activ
bacteri
ie
lipopolysaccharid
innat
immun
compon
ie
highmobl
group
box
activ
inhibit
enterocyt
migrat
lead
enterocyt
apoptosi
mice
model
via
nuclear
factor
kappa
light
chain
enhanc
activ
b
cell
nf
b
pathway
activ
wherea
inhibit
signal
intestin
epithelium
prevent
nec
develop
attenu
degre
enterocyt
apoptosi
mice
model
cell
cultur
develop
fetus
express
elev
level
end
gestat
overexpress
could
due
role
regul
prolifer
differenti
intestin
epithelium
embryogenet
period
persist
elev
express
intrauterin
life
increas
risk
nec
fetu
probabl
live
steril
quasisteril
environ
end
gestat
neonat
express
low
level
presenc
normal
intestin
microflora
signal
remain
inactiv
contrast
express
preterm
babi
high
prematur
intestin
colon
patholog
microflora
signal
could
overactiv
lead
decreas
abil
repair
howev
observ
prematur
infant
develop
nec
despit
seemingli
tonic
activ
suggest
signal
somehow
curtail
within
newborn
intestin
epithelium
thu
limit
propens
nec
develop
seem
therefor
consequ
exagger
signal
prematur
neonat
confin
counterregulatori
mechan
limit
consequ
activ
mechan
includ
intraand
extracellular
factor
probabl
may
influenc
microflora
composit
figur
heat
shock
protein
predomin
member
famili
intracellular
protein
activ
varieti
stressor
contribut
deliveri
target
protein
ubiquitinproteosom
system
degrad
cochaperon
molecul
name
carboxyl
terminu
protein
chip
protect
role
intestin
limit
signal
enterocyt
promot
chipmedi
ubiquitin
consequ
degrad
activ
significantli
increas
express
enterocyt
provid
mechan
autoinhibit
signal
figur
reduc
activ
hyperactiv
tlr
disrupt
balanc
induc
nec
contrari
upregul
lead
reduct
signal
figur
interestingli
extracellular
factor
possibl
affect
signal
epiderm
growth
factor
egf
fetu
continu
swallow
amniot
fluid
limit
amplif
signal
fetal
intestin
mucosa
cultur
enterocyt
expos
bacteri
product
thu
markedli
reduc
degre
proinflammatori
cytokin
releas
amniot
fluid
extrem
rich
egf
extracellular
factor
inhibit
signal
via
peroxisom
proliferatoractiv
receptor
gamma
ppar
nf
b
pathway
figur
import
factor
least
part
relat
tlr
signal
recent
explor
pathogenesi
nec
figur
signal
can
upregul
plateletactiv
factor
paf
express
thu
increas
risk
injuri
experiment
model
nec
accumul
ileal
bile
acid
caus
signific
injuri
small
intestin
act
concert
pathway
intestin
integr
restitut
requir
intercellular
connect
mediat
small
channel
name
gap
junction
rich
connexin
protein
proinflammatori
cytokin
ie
inf
caus
intern
connexin
therebi
impair
intercellular
connect
reduc
extent
intestin
restitut
figur
nearli
studi
nec
associ
infect
diseas
howev
specif
microb
identifi
determin
etiolog
factor
rather
surprisingli
specif
mechan
infect
contribut
nec
remain
unknown
hand
mani
pathogen
may
simul
pictur
nec
neonat
tabl
use
new
molecular
biolog
techniqu
provid
opportun
reexamin
unresolv
problem
recent
studi
identifi
abund
proteobacteria
includ
mani
commonli
observ
gramneg
pathogen
fecal
sampl
babi
develop
nec
addit
demonstr
find
includ
loss
gut
microbi
divers
deplet
enterococc
popul
fece
nec
develop
recent
correl
clinic
find
pneumatosi
intestinali
presenc
clostridi
speci
clostridium
butyricum
clostridium
paraputrificum
propos
data
suggest
nec
may
result
singl
caus
speci
like
current
undefin
dysbiosi
may
favor
activ
pathogen
transloc
across
epithelium
mainstay
prevent
treatment
nec
remain
correct
manag
fluid
intak
nutrit
prevent
infect
adequ
antibiot
therapi
basi
recent
evid
understand
pathogen
mechan
new
therapeut
approach
hypothes
recent
advanc
knowledg
pathogen
mechan
suggest
futur
treatment
may
involv
immunolog
approach
pharmacolog
inhibit
tlr
signal
manipul
intestin
environ
administr
specif
nutrient
option
test
clinic
trial
mani
other
develop
verifi
clinic
set
next
studi
figur
intervent
adopt
adequ
feed
strategi
use
specif
molecul
enter
nutrit
may
posit
impact
risk
nec
human
milk
abl
promot
matur
gastrointestin
tract
preterm
neonat
posit
effect
human
milk
attribut
sever
factor
ie
macrophag
lymphocyt
siga
lysozym
lactoferrin
oligosaccharid
nucleotid
cytokin
growth
factor
enzym
specif
compon
transfer
preterm
formula
definit
identifi
endotheli
nitric
oxid
import
regul
vascular
perfus
synthes
amino
acid
larginin
hypoargininemia
frequent
observ
preterm
neonat
may
predispos
nec
recent
polycarp
et
al
demonstr
enter
larginin
supplement
safe
administ
vlbw
neonat
appear
reduc
incid
stage
iii
nec
howev
larger
studi
need
evalu
effect
larginin
supplement
prevent
nec
vlbw
infant
enter
glutamin
supplement
decreas
gastrointestin
dysfunct
number
day
feed
withheld
seriou
infecti
episod
moreov
experiment
studi
shown
glutamin
play
import
role
maintain
function
integr
gut
serv
fuel
enterocyt
stimul
mucos
cell
prolifer
differenti
improv
mucu
qualiti
maintain
integr
tight
junction
improv
intestin
integr
turn
decreas
probabl
bacteri
transloc
system
spread
bacteria
howev
far
anim
studi
provid
direct
evid
hypothesi
protect
role
egf
demonstr
mainli
anim
model
nec
egf
contain
amniot
fluid
promot
epitheli
repair
inhibit
signal
figur
egf
test
one
small
trial
includ
case
neonat
studi
human
advoc
verifi
efficaci
egf
amniot
fluid
prevent
nec
studi
demonstr
egf
well
toler
produc
posit
measur
remodel
trophic
effect
gastrointestin
mucosa
short
chain
fatti
acid
scfa
deriv
ferment
undigest
carbohydr
intestin
microflora
import
effect
epitheli
function
matur
potent
antiinflammatori
power
mucosa
despit
potenti
therapeut
util
scfa
neonat
risk
nec
studi
test
efficaci
molecul
avail
moment
zinc
ubiquit
element
particip
mani
metabol
pathway
use
zinc
prevent
nec
support
evid
demonstr
role
zinc
mainten
epitheli
barrier
function
induct
adequ
immun
respons
figur
experiment
model
nec
recent
clinic
trial
demonstr
efficaci
oral
zinc
supplement
reduc
nec
preterm
neonat
administ
high
dose
signal
pharmacolog
upregul
within
intestin
mucosa
celastrol
novel
cell
permeabl
triterpenoid
antioxid
test
mice
model
nec
celastrol
reduc
enterocyt
apoptosi
attenu
sever
nec
studi
human
still
lack
time
possibl
hypothes
modul
tlr
signal
throughout
differ
way
indic
figur
studi
requir
establish
real
applic
novel
therapeut
option
prevent
treat
human
case
nec
rel
wellstudi
approach
manipul
gut
microbiom
administr
probiot
although
efficaci
prevent
treatment
nec
demonstr
articl
work
critic
need
determin
welltoler
effect
dose
strategi
identifi
longterm
effect
microbi
manipul
health
develop
tabl
extrapol
avail
evid
probiot
preterm
neonat
take
account
characterist
product
util
popul
includ
examin
studi
specif
strain
use
popul
develop
countri
may
effect
neonat
countri
may
differ
environment
genet
condit
thu
debat
whether
give
probiot
systemat
preterm
infant
still
ongo
american
pediatr
surgic
associ
outcom
clinic
trial
committe
systemat
review
conclud
support
recent
cochran
review
regard
use
prophylact
probiot
preterm
infant
weigh
less
g
reduc
incid
nec
howev
high
level
evid
recommend
routin
use
probiot
order
decreas
nec
occurr
mani
aspect
may
influenc
differ
result
obtain
differ
trial
particular
baselin
nec
rate
major
factor
affect
potenti
benefit
probiot
supplement
specif
popul
effect
probiot
decreas
dramat
area
occurr
nec
low
low
birth
weight
infant
henc
studi
need
benefit
area
establish
main
limit
futur
trial
larg
sampl
size
requir
demonstr
benefit
probiot
set
mihatsch
et
al
calcul
baselin
incid
nec
least
infant
per
group
would
requir
demonstr
reduct
rate
probiot
despit
larger
tabl
potenti
benefit
demonstr
limit
probiot
probiot
use
clinic
practic
neonat
intens
care
unit
higher
rate
nec
like
observ
benefit
probiot
supplement
probiot
secret
lactic
acid
lower
local
ph
inhibit
growth
pathogen
bacteria
multistrain
probiot
may
effect
singlestrain
product
probiot
commun
directli
pathogen
bacteria
modul
gene
express
order
reduc
bind
protein
host
epitheli
cell
extrem
lowbirthweight
infant
may
benefit
extent
observ
greater
gestat
age
bodi
birth
weight
probiot
stimul
product
secretori
immunoglobulin
posit
influenc
immun
respons
although
report
probioticrel
sepsi
limit
caution
use
consid
probiot
supplement
infant
greatest
risk
impair
mucos
barrier
polici
regard
storag
prepar
distribut
administr
document
probiot
ensur
patient
safeti
adopt
clinic
trial
current
underway
ongo
trial
target
sampl
size
larg
addit
mani
drug
current
use
neonat
intens
care
unit
may
modifi
microbiota
composit
ie
antibiot
probiot
thu
may
influenc
efficaci
intervent
microflora
manipul
gastric
acid
inhibitor
drug
larg
use
neonatolog
modifi
intestin
microflora
increas
risk
nec
limit
use
consid
immedi
efficaci
strategi
reduc
nec
incid
novel
perspect
manipul
intestin
microflora
repres
fecal
transplant
techniqu
proven
effect
treatment
refractori
coliti
clostridium
difficil
case
inflammatori
bowel
diseas
fecal
transplant
involv
direct
transfer
fecal
materi
healthi
donor
recipi
upper
lower
intestin
tract
data
current
avail
neonat
nec
import
limit
consid
hypothes
therapeut
option
neonatolog
ie
modal
transfer
fecal
materi
donor
recipi
andor
choic
donor
better
understand
earli
mechan
basi
nec
develop
offer
new
innov
therapeut
approach
sever
condit
improv
clinic
manag
limit
complic
associ
nec
futur
studi
start
central
role
epithelium
innat
immun
microbiota
would
essenti
explor
interact
main
pathogenet
factor
order
hypothes
new
efficaci
therapeut
strategi
welldesign
trial
select
popul
advoc
verifi
efficaci
new
pharmacolog
nutrit
approach
hypothes
review
